AstraZeneca PLC

AZNNYSEHealthcare● Active

$185.95

+$4.15(+2.28%)

Market Cap$288.4B

P/E Ratio—

52W High$212.71

52W Low$137.22

Avg Volume1.9M

Open$184.02

Beta0.21

Overview

AstraZeneca PLC (AZN) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

AZN · free cash flow · updated Jun 8, 2026

Core FCF metrics

AZN · FCF · TTM · margin & CAGR

Free cash flow was $11.77B for FY2025 (fiscal year ending 2025-12-31), up 61.7% year-over-year The FCF margin was 20.0%. Five-year CAGR stands at +39.9%.

FY2025 Free Cash Flow$11.77B▲ +61.7% YoY

Trailing 12M (TTM)$9.11Btrailing 4 quarters sum

FCF Margin20.0%$11.77B ÷ revenue

3-Year CAGR+17.6%FY2022 → FY2025

5-Year CAGR+39.9%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

AZN · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$14.57B(2.81B)$11.77B▲ +61.7%20.0%

FY2024$11.86B(4.59B)$7.28B▲ +10.8%13.4%

FY2023$10.35B(3.78B)$6.57B▼ 9.3%14.3%

FY2022$9.81B(2.57B)$7.24B▲ +92.3%16.3%

FY2021$5.96B(2.20B)$3.76B▲ +71.6%10.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

AZN · P/FCF · FCF yield · FCF per share

AstraZeneca PLC (AZN) trades at a FCF yield of 3.07% and a price-to-free-cash-flow ratio of 31.6x. FCF per share stands at $5.88, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

3.07%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$5.88

TTM FCF ÷ Shares Outstanding

Price / FCF

x31.6

Share Price ÷ FCF per Share

EV / FCF (TTM)

x35.6

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

AZN · cash flow statement · operating / investing / financing

For FY2025, AstraZeneca PLC generated $14.57B in operating cash flow and spent 2.81B in capital expenditures, yielding $11.77B in free cash flow.

Operating Activities

+$14.57B

Cash from core business operations

2025-12-31

Investing Activities

−$6.81B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$7.54B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($14.57B) − |CapEx| (2.81B) = FCF ($11.77B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

AZN vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

AstraZeneca PLCYOU

AZN

$11.77B+61.7%20.0%

60%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

AstraZeneca PLC (AZN) reported free cash flow of $11.77B for FY2025 (fiscal year ending 2025-12-31), up 61.7% year-over-year. The FCF margin was 20.0%.

Based on available data, AstraZeneca PLC has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $11.77B in FY2025. The 5-year CAGR stands at +39.9%.

AstraZeneca PLC's FCF yield is 3.07% and price-to-FCF ratio is 31.6x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

AZN free cash flow · 8 questions

AstraZeneca PLC free cash flow was $11.77B for FY2025, up 61.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $9.11B.

AZN free cash flowAZN FCFAZN FCF 2025AZN free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · AstraZeneca PLC · AstraZeneca PLC SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026